Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

Pharmerging Market Pharmerging Market Poised for Rapid Growth Amid Rising Healthcare Demands US, NY, UNITED STATES, March 15, 2025 /EIN ...

Early this year, Kamada announced that it expects continued double-digit growth – all while maintaining profitability – for ...

Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Emergen Research Logo The global Generic Drug Market size was USD 360.84 Billion in 2022 and is expected to register a rapid revenue CAGR o ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).